Podcasts about tandem meetings

Imugene Ltd (ASX: IMU, OTC: IUGNF) chief medical officer Dr. Paul Woodard and managing director and CEO Leslie Chong talked with Proactive's Tylah Tully about the latest results from the Phase 1b clinical trial of Azer-cel, the company's CD19 CAR-T therapy. Dr. Woodard, speaking from 2025 Tandem Meetings in Honolulu, shared the excitement around the trial's findings. Azer-cel is being developed for patients who have relapsed after multiple lines of treatment. The latest data reveals a 57% complete response rate, meaning no detectable lymphoma in these patients. Chong highlighted that the addition of a low dose of IL-2 to Azer-cel has contributed to T-cell proliferation, helping patients' immune systems fight back. She emphasised that seeing durable responses in patients who have exhausted multiple treatment options is a significant achievement. Dr. Woodard also underscored the importance of these results, stating that some patients are experiencing long-lasting remissions, with one individual remaining in complete remission for over ten months. These findings reinforce the potential of Azer-cel in addressing an unmet need in relapsed and refractory lymphoma patients. #Imugene #AzerCel #CAR_T #Biotech #Oncology #CancerResearch #ClinicalTrials #Lymphoma #MedicalBreakthrough #Investing

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL; Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL; and Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL; Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL; and Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL; Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL; and Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL; Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL; and Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL; Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL; and Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL; Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL; and Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don't miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this activity, participants should be better able to: Develop effective strategies for VOD risk assessment and diagnosis, including in the immediate pre- and post-HCT setting; Establish the presence of organ dysfunction in patients with a VOD diagnosis using currently available management tools; and Select appropriate treatment options for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures.

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don't miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this activity, participants should be better able to: Develop effective strategies for VOD risk assessment and diagnosis, including in the immediate pre- and post-HCT setting; Establish the presence of organ dysfunction in patients with a VOD diagnosis using currently available management tools; and Select appropriate treatment options for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures.

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don't miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this activity, participants should be better able to: Develop effective strategies for VOD risk assessment and diagnosis, including in the immediate pre- and post-HCT setting; Establish the presence of organ dysfunction in patients with a VOD diagnosis using currently available management tools; and Select appropriate treatment options for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures.

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don't miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this activity, participants should be better able to: Develop effective strategies for VOD risk assessment and diagnosis, including in the immediate pre- and post-HCT setting; Establish the presence of organ dysfunction in patients with a VOD diagnosis using currently available management tools; and Select appropriate treatment options for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures.

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don't miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this activity, participants should be better able to: Develop effective strategies for VOD risk assessment and diagnosis, including in the immediate pre- and post-HCT setting; Establish the presence of organ dysfunction in patients with a VOD diagnosis using currently available management tools; and Select appropriate treatment options for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures.

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don't miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this activity, participants should be better able to: Develop effective strategies for VOD risk assessment and diagnosis, including in the immediate pre- and post-HCT setting; Establish the presence of organ dysfunction in patients with a VOD diagnosis using currently available management tools; and Select appropriate treatment options for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures.

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don't miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this activity, participants should be better able to: Develop effective strategies for VOD risk assessment and diagnosis, including in the immediate pre- and post-HCT setting; Establish the presence of organ dysfunction in patients with a VOD diagnosis using currently available management tools; and Select appropriate treatment options for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures.

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don't miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this activity, participants should be better able to: Develop effective strategies for VOD risk assessment and diagnosis, including in the immediate pre- and post-HCT setting; Establish the presence of organ dysfunction in patients with a VOD diagnosis using currently available management tools; and Select appropriate treatment options for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures.

In this latest episode of ASTCT Talks, Dr. Andrés Gómez De León, a physician at the Universidad Autónoma de Nuevo León Hematology Service in Monterrey, Mexico, and Dr. Cristóbal Frutos, who is the Coordinator for the Bone Marrow transplant Unito the Hospital Central Instituto de Previsión Social in Asunción Paraguay, discuss the current state of transplant activities and the importance of having access to cell therapies worldwide. Dr. Frutos presented on this topic during the 2022 Tandem Meetings of ASTCT & CIBMTR.